Latest Monoclonal antibodies Stories
Improved Efficacy and Lower List Price than the Anti-TNFs Will Be the Key Drivers for Prescribing of Emerging Therapies, According to Findings from Decision Resources Group BURLINGTON, Mass.,
-Enhances Capabilities for the Precision Medicine in Immuno-oncology and Autoimmune Disease Areas- LOS ANGELES and LEIPZIG, Germany, Sept. 17, 2014 /PRNewswire/ -- ImaginAb, Inc.
SAN DIEGO, Sept. 16, 2014 /PRNewswire/ -- Denovo Biopharma, LLC, today announced that it has acquired enzastaurin, a late-stage oncology drug, from Eli Lilly and Company (NYSE: LLY).
According to new report from BCC Research, the global market for bioengineered protein drugs was valued at $151.9 billion in 2013 and is expected to reach about $157 billion in 2014.
NEW YORK, LONDON, BERLIN and PARIS, September 15, 2014 /PRNewswire/ -- SOURCE M/S.
- Currently no approved treatment options available for patients living with HS, a skin disease which impacts approximately 1 percent of the adult population worldwide1,2 COPENHAGEN, Denmark,
SAN DIEGO, Sept. 10, 2014 /PRNewswire/ -- MabVax Therapeutics Holdings, Inc.
Collaboration to Express Antibodies and Antigens based on Sutro's Technology Platform Xpress CF(TM) SAN FRANCISCO, Sept.
TNF-Alpha Inhibitors--Including Sales Leader Humira--Accounted for Over 90 Percent of the Psoriatic Arthritis Market, According to Findings from Decision Resources Group BURLINGTON, Mass.,
SAN DIEGO, Sept. 5, 2014 /PRNewswire/ -- Sorrento Therapeutics, Inc.
- The deadly nightshade, Atropa Belladonna, which possesses stupefying or poisonous properties.
- A sleeping-potion; a soporific.
- To mutter deliriously.
More Images (1 images) »